Incidence, Outcomes and Risk Factors of Recurrent Ventilator Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study.
COVID-19
ICU
acute respiratory distress syndrome
recurrence of VAP
ventilator-associated pneumonia
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Nov 2022
30 Nov 2022
Historique:
received:
10
10
2022
revised:
18
11
2022
accepted:
25
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Background: High incidence of ventilator associated pneumonia (VAP) has been reported in critically ill patients with COVID-19. Among these patients, we aimed to assess the incidence, outcomes and risk factors of VAP recurrences. Methods: We conducted an observational retrospective study in three French intensive care units (ICUs). Patients admitted for a documented COVID-19 from March 2020 to May 2021 and requiring mechanical ventilation (MV) for ≥48 h were included. The study main outcome was the incidence of VAP recurrences. Secondary outcomes were the duration of MV, ICU and hospital length of stay and mortality according to VAP and recurrences. We also assessed the factors associated with VAP recurrences. Results: During the study period, 398 patients met the inclusion criteria. A total of 236 (59%) of them had at least one VAP episode during their ICU stay and 109 (46%) of these patients developed at least one recurrence. The incidence of VAP recurrence considering death and extubation as competing events was 29.6% (IC = [0.250−0.343]). Seventy-eight percent of recurrences were due to the same bacteria (relapses). Patients with a VAP recurrence had a longer duration of MV as compared with one VAP and no VAP patients (41 (25−56) vs. 16 (8−30) and 10 (5−18) days; p < 0.001) and a longer ICU length of stay (46 (29−66) vs. 22 (12−36) and 14 (9−25) days; p < 0.001). The 90-day mortality was higher in the recurrence group as compared with the no VAP group only (31.2 vs. 21.0% (p = 0.021)). In a multivariate analysis including bacterial co-infection at admission, the use of immunosuppressive therapies and the bacteria responsible for the first VAP episode, the duration of MV was the only factor independently associated with VAP recurrence. Conclusion: In COVID-19 associated respiratory failure, recurrences affected 46% of patients with a first episode of VAP. VAP recurrences were mainly relapses and were associated with a prolonged duration of MV and ICU length of stay but not with a higher mortality. MV duration was the only factor associated with recurrences.
Identifiants
pubmed: 36498679
pii: jcm11237097
doi: 10.3390/jcm11237097
pmc: PMC9738672
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Crit Care. 2021 Feb 18;25(1):72
pubmed: 33602296
Crit Care. 2021 May 25;25(1):177
pubmed: 34034777
Am J Respir Crit Care Med. 2021 Oct 15;204(8):921-932
pubmed: 34409924
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Intensive Care Med. 2020 May;46(5):888-906
pubmed: 32157357
Crit Care. 2020 Jun 5;24(1):289
pubmed: 32503590
Ann Intensive Care. 2021 May 31;11(1):87
pubmed: 34057642
JAMA. 2003 Nov 19;290(19):2588-98
pubmed: 14625336
Intensive Care Med. 2020 Jun;46(6):1105-1108
pubmed: 32347323
Chest. 2007 Apr;131(4):954-63
pubmed: 17426195
Intensive Care Med. 2021 Feb;47(2):188-198
pubmed: 33388794
Intensive Care Med. 2020 Feb;46(2):245-265
pubmed: 31781835
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Clin Infect Dis. 2022 Jan 7;74(1):144-148
pubmed: 32604407
JAMA Intern Med. 2021 Jan 1;181(1):41-51
pubmed: 33080002
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Intensive Care Med. 2020 Dec;46(12):2200-2211
pubmed: 32728965
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Ann Intensive Care. 2020 Nov 23;10(1):158
pubmed: 33230710
J Intensive Care. 2021 Oct 18;9(1):64
pubmed: 34663481
Intensive Care Med. 2021 Nov;47(11):1181-1247
pubmed: 34599691
Crit Care Explor. 2021 Jun 29;3(7):e0482
pubmed: 34235460
Curr Opin Crit Care. 2022 Feb 1;28(1):74-82
pubmed: 34932525
J Infect Dis. 2021 Aug 2;224(3):395-406
pubmed: 33493287
Elife. 2020 Dec 17;9:
pubmed: 33331820
Crit Care. 2020 Dec 18;24(1):699
pubmed: 33339526
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546093
Autoimmun Rev. 2021 Feb;20(2):102726
pubmed: 33326855
Ann Fr Anesth Reanim. 2007 Jan;26(1):53-73
pubmed: 17174063
Ann Intensive Care. 2021 Jan 29;11(1):20
pubmed: 33512602